Skip to main content
. 2018 May 23;59(7):1148–1163. doi: 10.1194/jlr.M080788

Fig. 5.

Fig. 5.

FB1 does not reverse palmitate-induced insulin resistance and inflammation. L6 myotubes were pretreated with FB1 (50 μM) for 30 min and then incubated with 0.5 mM PA in the presence of FB1 for 18 h. A: Lipid species were identified by lipidomics as described in the Methods. B: Surface GLUT4 was measured as described in the Methods [n = 7; three-way ANOVA (insulin, PA, FB1)]. C, D: Expression of Ccl2 and Il6 after PA and FB1 exposure was measured by qPCR [n = 4; two-way ANOVA (PA, FB1)]. #Overall significant effect of inhibitor (two-way ANOVA; P < 0.05). *Significant effect of PA over BSA control (two-way ANOVA; P < 0.05). §Significant effect of insulin over unstimulated control (P < 0.05). DHCer, dihydroceramide; HexCer, hexosylceramide; SPM, sphingomyelin; LacCer, lactosylceramide; MeOH, methanol.